Drugs / PA-111
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06976489 | May → Jul 2025 overdue | hyperlipidemia, combined, 2 | Addpharma Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06932705 | Apr → May 2025 overdue | hyperlipidemia, combined, 2 | Addpharma Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PA-111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06932705 ↗ |
| Route | Oral | “PA-111 1Tab., Per Oral” NCT06932705 ↗ |